Probucol prevents lipid storage in macrophages - PubMed (original) (raw)
Probucol prevents lipid storage in macrophages
A Yamamoto et al. Atherosclerosis. 1986 Dec.
Abstract
Effects of probucol on lipid storage in macrophages in vitro in the presence of acetylated low density lipoprotein (acetyl-LDL) were observed using macrophage-like cells (UE-12) established from a human histiocytic lymphoma cell line (U-937). Under ordinary light microscopy as well as under electron microscopy we found that probucol added to the medium, either in ethanolic solution or bound to LDL, markedly prevented the development of macrophages into foam cells. Microscale enzymatic assay of cholesterol also showed that the intracellular accumulation of esterified cholesterol caused by acetyl-LDL was markedly decreased by the addition of probucol. The concentration of probucol added to the medium was almost comparable to the plasma concentration of the drug usually obtained in patients under treatment with probucol. The possibility that probucol interferes with the binding of acetyl-LDL to the receptors on the cell surface was suggested. The results of the present investigation coincide with the clinical findings that probucol causes a more marked regression of xanthomas than would be expected from the extent of lowering of LDL cholesterol.
Similar articles
- Effect of probucol on macrophages, leading to regression of xanthomas and atheromatous vascular lesions.
Yamamoto A, Hara H, Takaichi S, Wakasugi J, Tomikawa M. Yamamoto A, et al. Am J Cardiol. 1988 Jul 25;62(3):31B-36B. doi: 10.1016/s0002-9149(88)80048-1. Am J Cardiol. 1988. PMID: 3394651 - Probucol inhibits oxidative modification of low density lipoprotein.
Parthasarathy S, Young SG, Witztum JL, Pittman RC, Steinberg D. Parthasarathy S, et al. J Clin Invest. 1986 Feb;77(2):641-4. doi: 10.1172/JCI112349. J Clin Invest. 1986. PMID: 3944273 Free PMC article. - Probucol, high-density lipoprotein metabolism and reverse cholesterol transport.
Gwynne JT. Gwynne JT. Am J Cardiol. 1988 Jul 25;62(3):48B-51B. doi: 10.1016/s0002-9149(88)80051-1. Am J Cardiol. 1988. PMID: 2839973 Review. - Probucol: pharmacology and clinical application.
Zimetbaum P, Eder H, Frishman W. Zimetbaum P, et al. J Clin Pharmacol. 1990 Jan;30(1):3-9. doi: 10.1002/j.1552-4604.1990.tb03431.x. J Clin Pharmacol. 1990. PMID: 2406299 Review.
Cited by
- Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbit, an animal model for familial hypercholesterolemia.
Kita T, Nagano Y, Yokode M, Ishii K, Kume N, Ooshima A, Yoshida H, Kawai C. Kita T, et al. Proc Natl Acad Sci U S A. 1987 Aug;84(16):5928-31. doi: 10.1073/pnas.84.16.5928. Proc Natl Acad Sci U S A. 1987. PMID: 3475709 Free PMC article. - Co-treatment with probucol does not improve lung pathology in hydroxypropyl-β-cyclodextrin-treated Npc1-/- mice.
Erickson RP, Borbon IA. Erickson RP, et al. J Appl Genet. 2019 May;60(2):175-178. doi: 10.1007/s13353-019-00487-x. Epub 2019 Feb 28. J Appl Genet. 2019. PMID: 30815842 - Probucol. A reappraisal of its pharmacological properties and therapeutic use in hypercholesterolaemia.
Buckley MM, Goa KL, Price AH, Brogden RN. Buckley MM, et al. Drugs. 1989 Jun;37(6):761-800. doi: 10.2165/00003495-198937060-00002. Drugs. 1989. PMID: 2667936 Review. - High Density Lipoprotein-Based Therapeutics: Novel Mechanism of Probucol in Foam Cells.
Hafiane A, Ronca A, Kiss RS, Favari E. Hafiane A, et al. Front Cardiovasc Med. 2022 Apr 26;9:895031. doi: 10.3389/fcvm.2022.895031. eCollection 2022. Front Cardiovasc Med. 2022. PMID: 35557540 Free PMC article. No abstract available. - The effects of probucol on the progression of atherosclerosis in mature Watanabe heritable hyperlipidaemic rabbits.
Daugherty A, Zweifel BS, Schonfeld G. Daugherty A, et al. Br J Pharmacol. 1991 May;103(1):1013-8. doi: 10.1111/j.1476-5381.1991.tb12293.x. Br J Pharmacol. 1991. PMID: 1878742 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources